Loading study record…
The purpose of this study is to examine whether individual differences in acute responses to drugs co-vary across three drugs from different drug classes: alcohol, amphetamine and delta-9-tetrahydrocannabinol (THC). The investigators hypothesize that individuals who experience greater rewarding effects from one drug will also experience more rewarding effects from the other drugs.
Locally preserved from ClinicalTrials.govOpen ClinicalTrials.govlast source update 2016-11-29
What this record can show
Results are reported by the registry submitter and preserved exactly. They are not independent verification or a treatment recommendation.
Registry facts
Here, the investigators aim to investigate whether individuals exhibit similar responses to three different drugs from different classes. This study used a within-subjects design (total N = 24). All subjects received alcohol, amphetamine and delta-9-tetrahydrocannabinol (THC) in a double-blind, double-dummy fashion. Subjects completed six sessions wherein they received either alcohol, amphetamine, or THC, or corresponding placebos, on separate days. Subjects completed questionnaires about mood, general drug effects, and specific drug effects.
Linked local records
Local links use governed condition terms or exact source-reported intervention names. They are navigation candidates, not efficacy claims.
Research network
Interventions
This is a within-subjects, double-blind, placebo controlled design. We administered oral THC to healthy volunteers to measure their subjective response, which we later compared to their responses to two other drugs.
delta-9-tetrahydrocannabinolThis is a within-subjects, double-blind, placebo controlled design. We administered AMP to healthy volunteers to measure their subjective response, which we later compared to their responses to two other drugs.
d-AmphetamineThis is a within-subjects, double-blind, placebo controlled design. We administered alcohol to healthy volunteers to measure their subjective response, which we later compared to their responses to two other drugs.
AlcoholThis is a within-subjects, double-blind, placebo controlled design. We administered size 00 gelatin capsules containing dextrose to healthy volunteers as a control for when they received either amphetamine or THC.
Sugar PillsThis is a within-subjects, double-blind, placebo controlled design. We administered a drink containing cranberry juice plus 1% alcohol added as a taste mask.
Source-reported results
Results are reported by the registry submitter and preserved exactly. They are not independent verification or a treatment recommendation.
Drug effects will be measured using the Drug Effects Questionnaire (Fischman \& Foltin, 1991). The DEQ included 5 subscales; feeling, liking, and disliking the drug effect, feeling high, and wanting more of the drug. Each subscale ranged from 1(Not at all) to 100(Very much). The change in DFQ was assessed by the difference in measurements between baseline and 30 minutes after capsule administration and before drink administration. Baseline was measure 15 minutes prior to capsule administration.
Population: Participants who completed all sessions
| Group | N | Value | Spread / interval |
|---|---|---|---|
| AMP Arm | 24 | 4.79 | 7.22 |
| ALC Arm | 24 | 12.83 | 18.78 |
| THC Arm | 24 | 11.08 | 21.09 |
| AMP Placebo Arm | 24 | 12.17 | 19.90 |
| ALC Placebo Arm | 24 | 9.38 | 11.12 |
| THC Placebo Arm | 24 | 4.5 | 13.16 |
| AMP Arm | 24 | 16.08 | 27.47 |
| ALC Arm | 24 | 18.67 | 28.81 |
| THC Arm | 24 | 11.75 | 21.84 |
Eligibility
primary outcomes
Time frame: Measured 15 minutes prior to capsule administration and 30 minutes after capsule administration and before drink administration
Drug effects will be measured using the Drug Effects Questionnaire (Fischman \& Foltin, 1991). The DEQ included 5 subscales; feeling, liking, and disliking the drug effect, feeling high, and wanting more of the drug. Each subscale ranged from 1(Not at all) to 100(Very much). The change in DFQ was assessed by the difference in measurements between baseline and 30 minutes after capsule administration and before drink administration. Baseline was measure 15 minutes prior to capsule administration.
Time frame: Measured 15 minutes prior to capsule administration and 30 minutes after drink administration.
Drug effects will be measured using the Drug Effects Questionnaire (Fischman \& Foltin, 1991). The DEQ included 5 subscales; feeling, liking, and disliking the drug effect, feeling high, and wanting more of the drug. Each subscale ranged from 1(Not at all) to 100(Very much). The change in DFQ was assessed by the difference in measurements between baseline and 30 minutes after drink administration. Baseline was measure 15 minutes prior to capsule administration.
Time frame: Measured 15 minutes prior to capsule administration and 90 minutes after drink administration.
Drug effects will be measured using the Drug Effects Questionnaire (Fischman \& Foltin, 1991). The DEQ included 5 subscales; feeling, liking, and disliking the drug effect, feeling high, and wanting more of the drug. Each subscale ranged from 1(Not at all) to 100(Very much). The change in DFQ was assessed by the difference in measurements between baseline and 90 minutes after drink administration. Baseline was measure 15 minutes prior to capsule administration.
Time frame: Measured 15 minutes prior to capsule administration and 120 minutes after drink administration.
Drug effects will be measured using the Drug Effects Questionnaire (Fischman \& Foltin, 1991). The DEQ included 5 subscales; feeling, liking, and disliking the drug effect, feeling high, and wanting more of the drug. Each subscale ranged from 1(Not at all) to 100(Very much). The change in DFQ was assessed by the difference in measurements between baseline and 120 minutes after drink administration. Baseline was measure 15 minutes prior to capsule administration.
Publications
| AMP Placebo Arm | 24 | 9.0 | 18.42 |
| ALC Placebo Arm | 24 | 10.04 | 17.90 |
| THC Placebo Arm | 24 | 9.67 | 24.14 |
| AMP Arm | 24 | 4.21 | 9.43 |
| ALC Arm | 24 | 11.71 | 20.35 |
| THC Arm | 24 | 12.38 | 23.77 |
| AMP Placebo Arm | 24 | 10.71 | 18.75 |
| ALC Placebo Arm | 24 | 11.0 | 20.60 |
| THC Placebo Arm | 24 | 0.83 | 2.24 |
| AMP Arm | 24 | 3.29 | 6.06 |
| ALC Arm | 24 | 8.83 | 16.31 |
| THC Arm | 24 | 10.58 | 21.85 |
| AMP Placebo Arm | 24 | 6.96 | 18.44 |
| ALC Placebo Arm | 24 | 5.5 | 10.43 |
| THC Placebo Arm | 24 | 3.67 | 9.40 |
| AMP Arm | 24 | 14.21 | 25.26 |
| ALC Arm | 24 | 13.5 | 25.24 |
| THC Arm | 24 | 6.54 | 13.71 |
| AMP Placebo Arm | 24 | 5.63 | 12.59 |
| ALC Placebo Arm | 24 | 3.71 | 7.66 |
| THC Placebo Arm | 24 | 11.0 | 25.32 |
Drug effects will be measured using the Drug Effects Questionnaire (Fischman \& Foltin, 1991). The DEQ included 5 subscales; feeling, liking, and disliking the drug effect, feeling high, and wanting more of the drug. Each subscale ranged from 1(Not at all) to 100(Very much). The change in DFQ was assessed by the difference in measurements between baseline and 30 minutes after drink administration. Baseline was measure 15 minutes prior to capsule administration.
Population: Participants who completed all sessions
| Group | N | Value | Spread / interval |
|---|---|---|---|
| AMP Arm | 24 | 43.42 | 29.53 |
| ALC Arm | 24 | 76.83 | 20.01 |
| THC Arm | 24 | 38.25 | 33.45 |
| AMP Placebo Arm | 24 | 21.58 | 19.52 |
| ALC Placebo Arm | 24 | 17.83 | 22.56 |
| THC Placebo Arm | 24 | 18.63 | 20.69 |
| AMP Arm | 24 | 53.88 | 34.49 |
| ALC Arm | 24 | 45.08 | 28.43 |
| THC Arm | 24 | 28.75 | 30.05 |
| AMP Placebo Arm | 24 | 16.63 | 22.89 |
| ALC Placebo Arm | 24 | 14.38 | 20.78 |
| THC Placebo Arm | 24 | 25.29 | 28.76 |
| AMP Arm | 24 | 15.71 | 22.76 |
| ALC Arm | 24 | 43.96 | 28.96 |
| THC Arm | 24 | 25.63 | 35.03 |
| AMP Placebo Arm | 24 | 17.71 | 23.32 |
| ALC Placebo Arm | 24 | 16.68 | 26.83 |
| THC Placebo Arm | 24 | 15.79 | 20.66 |
| AMP Arm | 24 | 30.5 | 27.78 |
| ALC Arm | 24 | 50.38 | 32.15 |
| THC Arm | 24 | 31.75 | 35.00 |
| AMP Placebo Arm | 24 | 12.54 | 18.09 |
| ALC Placebo Arm | 24 | 11.5 | 21.80 |
| THC Placebo Arm | 24 | 12.96 | 20.22 |
| AMP Arm | 24 | 42.17 | 35.27 |
| ALC Arm | 24 | 24.75 | 32.67 |
| THC Arm | 24 | 17.46 | 25.18 |
| AMP Placebo Arm | 24 | 10.96 | 19.14 |
| ALC Placebo Arm | 24 | 10.0 | 18.32 |
| THC Placebo Arm | 24 | 18.96 | 28.97 |
Drug effects will be measured using the Drug Effects Questionnaire (Fischman \& Foltin, 1991). The DEQ included 5 subscales; feeling, liking, and disliking the drug effect, feeling high, and wanting more of the drug. Each subscale ranged from 1(Not at all) to 100(Very much). The change in DFQ was assessed by the difference in measurements between baseline and 90 minutes after drink administration. Baseline was measure 15 minutes prior to capsule administration.
Population: Participants who completed all sessions
| Group | N | Value | Spread / interval |
|---|---|---|---|
| AMP Arm | 24 | 34.92 | 24.75 |
| ALC Arm | 24 | 61.21 | 24.02 |
| THC Arm | 24 | 31.54 | 31.41 |
| AMP Placebo Arm | 24 | 16.46 | 18.97 |
| ALC Placebo Arm | 24 | 12.75 | 18.74 |
| THC Placebo Arm | 24 | 13.17 | 19.05 |
| AMP Arm | 24 | 55.67 | 31.45 |
| ALC Arm | 24 | 29.92 | 28.57 |
| THC Arm | 24 | 20.08 | 26.32 |
| AMP Placebo Arm | 24 | 10.42 | 18.22 |
| ALC Placebo Arm | 24 | 11.38 | 19.35 |
| THC Placebo Arm | 24 | 13.25 | 22.87 |
| AMP Arm | 24 | 16.54 | 21.60 |
| ALC Arm | 24 | 50.46 | 26.47 |
| THC Arm | 24 | 23.25 | 29.72 |
| AMP Placebo Arm | 24 | 17.54 | 26.16 |
| ALC Placebo Arm | 24 | 15.33 | 24.85 |
| THC Placebo Arm | 24 | 15.96 | 24.91 |
| AMP Arm | 24 | 27.92 | 24.57 |
| ALC Arm | 24 | 41.83 | 30.74 |
| THC Arm | 24 | 29.21 | 32.78 |
| AMP Placebo Arm | 24 | 6.83 | 12.47 |
| ALC Placebo Arm | 24 | 7.25 | 13.50 |
| THC Placebo Arm | 24 | 7.58 | 12.65 |
| AMP Arm | 24 | 50.21 | 36.06 |
| ALC Arm | 24 | 25.88 | 35.11 |
| THC Arm | 24 | 16.54 | 23.69 |
| AMP Placebo Arm | 24 | 6.54 | 15.33 |
| ALC Placebo Arm | 24 | 7.71 | 16.59 |
| THC Placebo Arm | 24 | 12.88 | 21.88 |
Drug effects will be measured using the Drug Effects Questionnaire (Fischman \& Foltin, 1991). The DEQ included 5 subscales; feeling, liking, and disliking the drug effect, feeling high, and wanting more of the drug. Each subscale ranged from 1(Not at all) to 100(Very much). The change in DFQ was assessed by the difference in measurements between baseline and 120 minutes after drink administration. Baseline was measure 15 minutes prior to capsule administration.
Population: Participants who completed all sessions
| Group | N | Value | Spread / interval |
|---|---|---|---|
| AMP Arm | 24 | 27.08 | 22.38 |
| ALC Arm | 24 | 43.92 | 24.18 |
| THC Arm | 24 | 24.08 | 29.28 |
| AMP Placebo Arm | 24 | 11.92 | 14.26 |
| ALC Placebo Arm | 24 | 7.96 | 14.08 |
| THC Placebo Arm | 24 | 7.88 | 14.65 |
| AMP Arm | 24 | 43.75 | 36.08 |
| ALC Arm | 24 | 23.79 | 25.61 |
| THC Arm | 24 | 18 | 27.26 |
| AMP Placebo Arm | 24 | 7.04 | 13.90 |
| ALC Placebo Arm | 24 | 4.83 | 11.49 |
| THC Placebo Arm | 24 | 8.67 | 16.86 |
| AMP Arm | 24 | 11.92 | 19.56 |
| ALC Arm | 24 | 44.92 | 31.37 |
| THC Arm | 24 | 19.63 | 27.21 |
| AMP Placebo Arm | 24 | 13.38 | 22.39 |
| ALC Placebo Arm | 24 | 11.08 | 23.89 |
| THC Placebo Arm | 24 | 8.88 | 18.69 |
| AMP Arm | 24 | 18.88 | 21.43 |
| ALC Arm | 24 | 29.38 | 25.77 |
| THC Arm | 24 | 21.96 | 30.06 |
| AMP Placebo Arm | 24 | 5.04 | 8.12 |
| ALC Placebo Arm | 24 | 5.08 | 11.20 |
| THC Placebo Arm | 24 | 4.83 | 10.45 |
| AMP Arm | 24 | 45.38 | 34.86 |
| ALC Arm | 24 | 17.5 | 27.95 |
| THC Arm | 24 | 9.92 | 18.06 |
| AMP Placebo Arm | 24 | 3.13 | 5.53 |
| ALC Placebo Arm | 24 | 6.54 | 15.59 |
| THC Placebo Arm | 24 | 9.88 | 19.63 |
Drug effects will be measured using the Drug Effects Questionnaire (Fischman \& Foltin, 1991). The DEQ included 5 subscales; feeling, liking, and disliking the drug effect, feeling high, and wanting more of the drug. Each subscale ranged from 1(Not at all) to 100(Very much). The change in DFQ was assessed by the difference in measurements between baseline and 150 minutes after drink administration. Baseline was measure 15 minutes prior to capsule administration.
Population: Participants who completed all sessions
| Group | N | Value | Spread / interval |
|---|---|---|---|
| AMP Arm | 24 | 19.79 | 17.72 |
| ALC Arm | 24 | 30.83 | 22.52 |
| THC Arm | 24 | 18.63 | 25.28 |
| AMP Placebo Arm | 24 | 5.83 | 10.72 |
| ALC Placebo Arm | 24 | 4.63 | 10.48 |
| THC Placebo Arm | 24 | 4.63 | 7.80 |
| AMP Arm | 24 | 39.5 | 34.58 |
| ALC Arm | 24 | 21.33 | 24.74 |
| THC Arm | 24 | 11.71 | 19.22 |
| AMP Placebo Arm | 24 | 6.74 | 14.88 |
| ALC Placebo Arm | 24 | 2.42 | 6.76 |
| THC Placebo Arm | 24 | 4.96 | 14.48 |
| AMP Arm | 24 | 11.25 | 20.64 |
| ALC Arm | 24 | 40.75 | 32.31 |
| THC Arm | 24 | 17.79 | 26.78 |
| AMP Placebo Arm | 24 | 8.09 | 21.80 |
| ALC Placebo Arm | 24 | 4.29 | 13.84 |
| THC Placebo Arm | 24 | 6.42 | 15.69 |
| AMP Arm | 24 | 16.33 | 18.68 |
| ALC Arm | 24 | 20.46 | 23.70 |
| THC Arm | 24 | 14.75 | 20.27 |
| AMP Placebo Arm | 24 | 2.87 | 4.48 |
| ALC Placebo Arm | 24 | 2.13 | 4.83 |
| THC Placebo Arm | 24 | 1.96 | 4.56 |
| AMP Arm | 24 | 44.08 | 34.63 |
| ALC Arm | 24 | 12.58 | 24.39 |
| THC Arm | 24 | 9.38 | 18.95 |
| AMP Placebo Arm | 24 | 2.87 | 10.55 |
| ALC Placebo Arm | 24 | 5.04 | 12.75 |
| THC Placebo Arm | 24 | 6.21 | 15.19 |
Drug effects will be measured using the Drug Effects Questionnaire (Fischman \& Foltin, 1991). The DEQ included 5 subscales; feeling, liking, and disliking the drug effect, feeling high, and wanting more of the drug. Each subscale ranged from 1(Not at all) to 100(Very much). The change in DFQ was assessed by the difference in measurements between baseline and 180 minutes after drink administration. Baseline was measure 15 minutes prior to capsule administration.
Population: Participants who completed all sessions
| Group | N | Value | Spread / interval |
|---|---|---|---|
| AMP Arm | 24 | 16.13 | 17.06 |
| ALC Arm | 24 | 22.21 | 19.71 |
| THC Arm | 24 | 15.67 | 24.63 |
| AMP Placebo Arm | 24 | 3.5 | 8.548 |
| ALC Placebo Arm | 24 | 2.08 | 5.01 |
| THC Placebo Arm | 24 | 2.54 | 4.59 |
| AMP Arm | 24 | 31.08 | 34.86 |
| ALC Arm | 24 | 9.04 | 14.29 |
| THC Arm | 24 | 7.33 | 15.82 |
| AMP Placebo Arm | 24 | 2.54 | 11.23 |
| ALC Placebo Arm | 24 | 1.75 | 7.56 |
| THC Placebo Arm | 24 | 4.0 | 12.47 |
| AMP Arm | 24 | 11.54 | 25.17 |
| ALC Arm | 24 | 29.5 | 34.28 |
| THC Arm | 24 | 16.13 | 28.42 |
| AMP Placebo Arm | 24 | 4.25 | 17.24 |
| ALC Placebo Arm | 24 | 4.29 | 16.80 |
| THC Placebo Arm | 24 | 4.63 | 13.65 |
| AMP Arm | 24 | 11.67 | 15.29 |
| ALC Arm | 24 | 14.13 | 19.36 |
| THC Arm | 24 | 11.79 | 18.36 |
| AMP Placebo Arm | 24 | 1.63 | 4.92 |
| ALC Placebo Arm | 24 | 1.25 | 3.30 |
| THC Placebo Arm | 24 | 1.04 | 3.30 |
| AMP Arm | 24 | 38.38 | 34.54 |
| ALC Arm | 24 | 7.0 | 19.77 |
| THC Arm | 24 | 10.04 | 18.61 |
| AMP Placebo Arm | 24 | 2.46 | 10.99 |
| ALC Placebo Arm | 24 | 4.04 | 12.22 |
| THC Placebo Arm | 24 | 5.04 | 12.89 |
Drug effects will be measured using the Drug Effects Questionnaire (Fischman \& Foltin, 1991). The DEQ included 5 subscales; feeling, liking, and disliking the drug effect, feeling high, and wanting more of the drug. Each subscale ranged from 1(Not at all) to 100(Very much). The change in DFQ was assessed by the difference in measurements between baseline and 210 minutes after drink administration. Baseline was measure 15 minutes prior to capsule administration.
Population: Participants who completed all sessions
| Group | N | Value | Spread / interval |
|---|---|---|---|
| AMP Arm | 24 | 11.08 | 16.71 |
| ALC Arm | 24 | 12.88 | 15.88 |
| THC Arm | 24 | 5.79 | 10.91 |
| AMP Placebo Arm | 24 | 2.17 | 5.74 |
| ALC Placebo Arm | 24 | 0.96 | 2.74 |
| THC Placebo Arm | 24 | 1.08 | 2.75 |
| AMP Arm | 24 | 18.38 | 31.38 |
| ALC Arm | 24 | 7.33 | 14.62 |
| THC Arm | 24 | 4.88 | 10.41 |
| AMP Placebo Arm | 24 | 1.96 | 7.04 |
| ALC Placebo Arm | 24 | 0.25 | 0.74 |
| THC Placebo Arm | 24 | 4.38 | 13.73 |
| AMP Arm | 24 | 8.54 | 24.16 |
| ALC Arm | 24 | 22.71 | 30.79 |
| THC Arm | 24 | 6.83 | 15.46 |
| AMP Placebo Arm | 24 | 7.46 | 23.16 |
| ALC Placebo Arm | 24 | 1.29 | 3.82 |
| THC Placebo Arm | 24 | 4.54 | 15.14 |
| AMP Arm | 24 | 6.25 | 9.88 |
| ALC Arm | 24 | 9.21 | 15.84 |
| THC Arm | 24 | 4.96 | 11.02 |
| AMP Placebo Arm | 24 | 0.33 | 1.05 |
| ALC Placebo Arm | 24 | 0.83 | 1.76 |
| THC Placebo Arm | 24 | 0.42 | 1.32 |
| AMP Arm | 24 | 32.5 | 31.84 |
| ALC Arm | 24 | 4.54 | 17.72 |
| THC Arm | 24 | 8.79 | 17.04 |
| AMP Placebo Arm | 24 | 2.25 | 8.19 |
| ALC Placebo Arm | 24 | 3.83 | 12.09 |
| THC Placebo Arm | 24 | 6.17 | 14.65 |
Specific drug effects will be measured using the Addiction Research Center Inventory (Martin et al. 1971). The ARCI measures effects specific to drug classes, including the effects of AMP-like drugs (A scale, 0 to 11), morphine and benzedrine like drugs (MBG scale, 0 to 14), lysergic acid-like drugs (LSD scale, 0 to 14), benzedrine-like drugs (BG scale, 0 to 13), pentobarbital-chlorpromazine and ALC-like drugs (PCAG scale, 0 to 15), and cannabis-like drugs (M scale, 0 to 12). We used this questionnaire as a manipulation check to ensure that the drugs produced their typical drug-specific effects in this study. For example, zero value of A sacle would be minimum report of amphetamine-like drug effects, and 11 would be maximum report of amphetamine-like effects. The change in ARCI was assessed by the difference in measurements between baseline and 30 minutes after capsule administration and before drink administration. Baseline was measure 15 minutes prior to capsule administration.
Population: Participants who completed all sessions
| Group | N | Value | Spread / interval |
|---|---|---|---|
| AMP Arm | 24 | -0.17 | 0.92 |
| ALC Arm | 24 | 0.25 | 1.33 |
| THC Arm | 24 | -0.04 | 1.16 |
| AMP Placebo Arm | 24 | -0.25 | 0.61 |
| ALC Placebo Arm | 24 | -0.17 | 1.2 |
| THC Placebo Arm | 24 | 0.54 | 0.88 |
| AMP Arm | 24 | -0.58 | 1.44 |
| ALC Arm | 24 | -0.29 | 1.27 |
| THC Arm | 24 | -0.71 | 1.88 |
| AMP Placebo Arm | 24 | -0.58 | 0.65 |
| ALC Placebo Arm | 24 | -0.67 | 1.46 |
| THC Placebo Arm | 24 | 0.33 | 1.37 |
| AMP Arm | 24 | 0.13 | 0.85 |
| ALC Arm | 24 | 0.33 | 0.82 |
| THC Arm | 24 | 0.38 | 1.69 |
| AMP Placebo Arm | 24 | 0.13 | 0.99 |
| ALC Placebo Arm | 24 | 0.08 | 0.97 |
| THC Placebo Arm | 24 | -0.17 | 0.64 |
| AMP Arm | 24 | -0.46 | 1.02 |
| ALC Arm | 24 | -0.75 | 1.67 |
| THC Arm | 24 | -0.79 | 2.0 |
| AMP Placebo Arm | 24 | -1.17 | 1.52 |
| ALC Placebo Arm | 24 | -0.92 | 1.21 |
| THC Placebo Arm | 24 | 0.25 | 1.03 |
| AMP Arm | 24 | 0.58 | 1.21 |
| ALC Arm | 24 | 1.29 | 2.39 |
| THC Arm | 24 | 2.92 | 2.73 |
| AMP Placebo Arm | 24 | 1.96 | 2.44 |
| ALC Placebo Arm | 24 | 0.92 | 1.61 |
| THC Placebo Arm | 24 | 0.42 | 1.02 |
| AMP Arm | 24 | 0.08 | 1.06 |
| ALC Arm | 24 | 0.83 | 1.81 |
| THC Arm | 24 | 0.42 | 1.32 |
| AMP Placebo Arm | 24 | 0.5 | 1.25 |
| ALC Placebo Arm | 24 | 0.33 | 1.05 |
| THC Placebo Arm | 24 | 0.42 | 1.18 |
Specific drug effects will be measured using the Addiction Research Center Inventory (Martin et al. 1971). The ARCI measures effects specific to drug classes, including the effects of AMP-like drugs (A scale, 0 to 11), morphine and benzedrine like drugs (MBG scale, 0 to 14), lysergic acid-like drugs (LSD scale, 0 to 14), benzedrine-like drugs (BG scale, 0 to 13), pentobarbital-chlorpromazine and ALC-like drugs (PCAG scale, 0 to 15), and cannabis-like drugs (M scale, 0 to 12). We used this questionnaire as a manipulation check to ensure that the drugs produced their typical drug-specific effects in this study. For example, zero value of A sacle would be minimum report of amphetamine-like drug effects, and 11 would be maximum report of amphetamine-like effects. The change in ARCI was assessed by the difference in measurements between baseline and 30 minutes after drink administration. Baseline was measure 15 minutes prior to capsule administration.
Population: Participants who completed all sessions
| Group | N | Value | Spread / interval |
|---|---|---|---|
| AMP Arm | 24 | 2.88 | 2.80 |
| ALC Arm | 24 | 1.92 | 2.64 |
| THC Arm | 24 | 0.17 | 0.96 |
| AMP Placebo Arm | 24 | 0 | 0.93 |
| ALC Placebo Arm | 24 | -0.33 | 1.61 |
| THC Placebo Arm | 24 | 0.71 | 1.40 |
| AMP Arm | 24 | 3.71 | 4.59 |
| ALC Arm | 24 | 1.38 | 4.79 |
| THC Arm | 24 | -0.54 | 3.04 |
| AMP Placebo Arm | 24 | 0 | 1.77 |
| ALC Placebo Arm | 24 | -1.17 | 2.75 |
| THC Placebo Arm | 24 | 0.88 | 3.26 |
| AMP Arm | 24 | 1.13 | 2.03 |
| ALC Arm | 24 | 2.63 | 2.32 |
| THC Arm | 24 | 1.54 | 2.47 |
| AMP Placebo Arm | 24 | 0.33 | 1.09 |
| ALC Placebo Arm | 24 | 0.29 | 1.12 |
| THC Placebo Arm | 24 | 0.13 | 1.23 |
| AMP Arm | 24 | 1.63 | 2.28 |
| ALC Arm | 24 | -0.88 | 3.00 |
| THC Arm | 24 | -1.38 | 1.64 |
| AMP Placebo Arm | 24 | -0.83 | 1.31 |
| ALC Placebo Arm | 24 | -0.96 | 1.99 |
| THC Placebo Arm | 24 | 0.04 | 1.46 |
| AMP Arm | 24 | -1 | 1.89 |
| ALC Arm | 24 | 3.71 | 4.29 |
| THC Arm | 24 | 2.96 | 3.33 |
| AMP Placebo Arm | 24 | 2.25 | 3.55 |
| ALC Placebo Arm | 24 | 1.54 | 3.24 |
| THC Placebo Arm | 24 | 1.13 | 2.35 |
| AMP Arm | 24 | 3.21 | 2.73 |
| ALC Arm | 24 | 3.42 | 2.22 |
| THC Arm | 24 | 2.04 | 2.56 |
| AMP Placebo Arm | 24 | 0.42 | 0.93 |
| ALC Placebo Arm | 24 | 0.29 | 1.16 |
| THC Placebo Arm | 24 | 0.96 | 1.78 |
Specific drug effects will be measured using the Addiction Research Center Inventory (Martin et al. 1971). The ARCI measures effects specific to drug classes, including the effects of AMP-like drugs (A scale, 0 to 11), morphine and benzedrine like drugs (MBG scale, 0 to 14), lysergic acid-like drugs (LSD scale, 0 to 14), benzedrine-like drugs (BG scale, 0 to 13), pentobarbital-chlorpromazine and ALC-like drugs (PCAG scale, 0 to 15), and cannabis-like drugs (M scale, 0 to 12). We used this questionnaire as a manipulation check to ensure that the drugs produced their typical drug-specific effects in this study. For example, zero value of A sacle would be minimum report of amphetamine-like drug effects, and 11 would be maximum report of amphetamine-like effects. The change in ARCI was assessed by the difference in measurements between baseline and 90 minutes after drink administration. Baseline was measure 15 minutes prior to capsule administration.
Population: Participants who completed all sessions
| Group | N | Value | Spread / interval |
|---|---|---|---|
| AMP Arm | 24 | 2.96 | 2.49 |
| ALC Arm | 24 | 0.29 | 2.44 |
| THC Arm | 24 | 0 | 1.22 |
| AMP Placebo Arm | 24 | -0.33 | 0.76 |
| ALC Placebo Arm | 24 | -0.58 | 1.28 |
| THC Placebo Arm | 24 | -0.08 | 1.02 |
| AMP Arm | 24 | 3.67 | 4.86 |
| ALC Arm | 24 | -0.38 | 2.45 |
| THC Arm | 24 | -0.83 | 2.55 |
| AMP Placebo Arm | 24 | -0.29 | 0.86 |
| ALC Placebo Arm | 24 | -1.29 | 2.93 |
| THC Placebo Arm | 24 | -0.13 | 0.95 |
| AMP Arm | 24 | 1.08 | 1.89 |
| ALC Arm | 24 | 1.79 | 1.93 |
| THC Arm | 24 | 1.42 | 2.69 |
| AMP Placebo Arm | 24 | -0.04 | 0.95 |
| ALC Placebo Arm | 24 | 0.29 | 1.12 |
| THC Placebo Arm | 24 | 0.08 | 0.93 |
| AMP Arm | 24 | 2.17 | 2.39 |
| ALC Arm | 24 | -2.54 | 2.40 |
| THC Arm | 24 | -1.71 | 2.03 |
| AMP Placebo Arm | 24 | -1.29 | 1.63 |
| ALC Placebo Arm | 24 | -1.13 | 1.57 |
| THC Placebo Arm | 24 | -0.67 | 1.46 |
| AMP Arm | 24 | -1.21 | 2.17 |
| ALC Arm | 24 | 6.21 | 2.92 |
| THC Arm | 24 | 3.54 | 3.68 |
| AMP Placebo Arm | 24 | 2.67 | 2.96 |
| ALC Placebo Arm | 24 | 1.92 | 3.22 |
| THC Placebo Arm | 24 | 1.58 | 1.91 |
| AMP Arm | 24 | 2.63 | 2.46 |
| ALC Arm | 24 | 2.25 | 2.51 |
| THC Arm | 24 | 2.04 | 2.63 |
| AMP Placebo Arm | 24 | 0.42 | 0.97 |
| ALC Placebo Arm | 24 | 0.13 | 0.80 |
| THC Placebo Arm | 24 | 0.29 | 0.62 |
Specific drug effects will be measured using the Addiction Research Center Inventory (Martin et al. 1971). The ARCI measures effects specific to drug classes, including the effects of AMP-like drugs (A scale, 0 to 11), morphine and benzedrine like drugs (MBG scale, 0 to 14), lysergic acid-like drugs (LSD scale, 0 to 14), benzedrine-like drugs (BG scale, 0 to 13), pentobarbital-chlorpromazine and ALC-like drugs (PCAG scale, 0 to 15), and cannabis-like drugs (M scale, 0 to 12). We used this questionnaire as a manipulation check to ensure that the drugs produced their typical drug-specific effects in this study. For example, zero value of A sacle would be minimum report of amphetamine-like drug effects, and 11 would be maximum report of amphetamine-like effects.The change in ARCI was assessed by the difference in measurements between baseline and 120 minutes after drink administration. Baseline was measure 15 minutes prior to capsule administration.
Population: Participants who completed all sessions
| Group | N | Value | Spread / interval |
|---|---|---|---|
| AMP Arm | 24 | 2.17 | 2.06 |
| ALC Arm | 24 | -0.33 | 1.34 |
| THC Arm | 24 | -0.08 | 1.21 |
| AMP Placebo Arm | 24 | -0.17 | 0.70 |
| ALC Placebo Arm | 24 | -0.71 | 1.37 |
| THC Placebo Arm | 24 | -0.04 | 0.86 |
| AMP Arm | 24 | 3.33 | 4.35 |
| ALC Arm | 24 | -1.13 | 2.13 |
| THC Arm | 24 | -0.96 | 2.60 |
| AMP Placebo Arm | 24 | -0.125 | 0.85 |
| ALC Placebo Arm | 24 | -1.29 | 2.97 |
| THC Placebo Arm | 24 | -0.08 | 0.65 |
| AMP Arm | 24 | 0.38 | 1.93 |
| ALC Arm | 24 | 0.79 | 1.28 |
| THC Arm | 24 | 1 | 2.83 |
| AMP Placebo Arm | 24 | -0.13 | 1.15 |
| ALC Placebo Arm | 24 | 0.04 | 1.16 |
| THC Placebo Arm | 24 | -0.08 | 0.93 |
| AMP Arm | 24 | 1.67 | 2.12 |
| ALC Arm | 24 | -2.04 | 1.73 |
| THC Arm | 24 | -1.54 | 1.64 |
| AMP Placebo Arm | 24 | -1 | 1.35 |
| ALC Placebo Arm | 24 | -0.83 | 1.55 |
| THC Placebo Arm | 24 | -0.38 | 1.58 |
| AMP Arm | 24 | -1.08 | 2.02 |
| ALC Arm | 24 | 5.46 | 2.93 |
| THC Arm | 24 | 2.88 | 3.49 |
| AMP Placebo Arm | 24 | 1.71 | 2.65 |
| ALC Placebo Arm | 24 | 1.63 | 2.76 |
| THC Placebo Arm | 24 | 1.08 | 1.98 |
| AMP Arm | 24 | 1.83 | 2.46 |
| ALC Arm | 24 | 1.08 | 1.56 |
| THC Arm | 24 | 1.42 | 2.04 |
| AMP Placebo Arm | 24 | 0.25 | 0.85 |
| ALC Placebo Arm | 24 | -0.04 | 0.86 |
| THC Placebo Arm | 24 | 0.17 | 0.56 |
Specific drug effects will be measured using the Addiction Research Center Inventory (Martin et al. 1971). The ARCI measures effects specific to drug classes, including the effects of AMP-like drugs (A scale, 0 to 11), morphine and benzedrine like drugs (MBG scale, 0 to 14), lysergic acid-like drugs (LSD scale, 0 to 14), benzedrine-like drugs (BG scale, 0 to 13), pentobarbital-chlorpromazine and ALC-like drugs (PCAG scale, 0 to 15), and cannabis-like drugs (M scale, 0 to 12). We used this questionnaire as a manipulation check to ensure that the drugs produced their typical drug-specific effects in this study. For example, zero value of A sacle would be minimum report of amphetamine-like drug effects, and 11 would be maximum report of amphetamine-like effects.The change in ARCI was assessed by the difference in measurements between baseline and 150 minutes after drink administration. Baseline was measure 15 minutes prior to capsule administration.
Population: Participants who completed all sessions
| Group | N | Value | Spread / interval |
|---|---|---|---|
| AMP Arm | 24 | 2.29 | 2.61 |
| ALC Arm | 24 | -0.54 | 1.14 |
| THC Arm | 24 | -0.17 | 1.63 |
| AMP Placebo Arm | 24 | -0.13 | 0.69 |
| ALC Placebo Arm | 24 | -0.54 | 1.47 |
| THC Placebo Arm | 24 | -0.08 | 0.83 |
| AMP Arm | 24 | 2.96 | 4.39 |
| ALC Arm | 24 | -1.54 | 1.96 |
| THC Arm | 24 | -0.96 | 2.39 |
| AMP Placebo Arm | 24 | 0.13 | 0.76 |
| ALC Placebo Arm | 24 | -1.25 | 2.88 |
| THC Placebo Arm | 24 | -0.08 | 0.88 |
| AMP Arm | 24 | 0.5 | 1.59 |
| ALC Arm | 24 | 0.79 | 1.35 |
| THC Arm | 24 | 0.58 | 2.22 |
| AMP Placebo Arm | 24 | 0.09 | 1.08 |
| ALC Placebo Arm | 24 | -0.13 | 1.03 |
| THC Placebo Arm | 24 | -0.17 | 0.82 |
| AMP Arm | 24 | 1.75 | 2.31 |
| ALC Arm | 24 | -2.04 | 1.65 |
| THC Arm | 24 | -1.29 | 1.86 |
| AMP Placebo Arm | 24 | -0.43 | 1.31 |
| ALC Placebo Arm | 24 | -0.67 | 1.24 |
| THC Placebo Arm | 24 | -0.42 | 1.28 |
| AMP Arm | 24 | -1 | 1.64 |
| ALC Arm | 24 | 5.46 | 2.95 |
| THC Arm | 24 | 2.58 | 3.16 |
| AMP Placebo Arm | 24 | 0.65 | 2.17 |
| ALC Placebo Arm | 24 | 1.58 | 2.96 |
| THC Placebo Arm | 24 | 0.79 | 1.79 |
| AMP Arm | 24 | 1.54 | 1.91 |
| ALC Arm | 24 | 0.75 | 1.33 |
| THC Arm | 24 | 0.83 | 1.83 |
| AMP Placebo Arm | 24 | 0.22 | 0.74 |
| ALC Placebo Arm | 24 | -0.21 | 0.78 |
| THC Placebo Arm | 24 | 0.08 | 0.41 |
Specific drug effects will be measured using the Addiction Research Center Inventory (Martin et al. 1971). The ARCI measures effects specific to drug classes, including the effects of AMP-like drugs (A scale, 0 to 11), morphine and benzedrine like drugs (MBG scale, 0 to 14), lysergic acid-like drugs (LSD scale, 0 to 14), benzedrine-like drugs (BG scale, 0 to 13), pentobarbital-chlorpromazine and ALC-like drugs (PCAG scale, 0 to 15), and cannabis-like drugs (M scale, 0 to 12). We used this questionnaire as a manipulation check to ensure that the drugs produced their typical drug-specific effects in this study. For example, zero value of A sacle would be minimum report of amphetamine-like drug effects, and 11 would be maximum report of amphetamine-like effects.The change in ARCI was assessed by the difference in measurements between baseline and 180 minutes after drink administration. Baseline was measure 15 minutes prior to capsule administration.
Population: Participants who completed all sessions
| Group | N | Value | Spread / interval |
|---|---|---|---|
| AMP Arm | 24 | 1.58 | 2.26 |
| ALC Arm | 24 | -0.75 | 1.19 |
| THC Arm | 24 | -0.21 | 1.44 |
| AMP Placebo Arm | 24 | -0.04 | 0.91 |
| ALC Placebo Arm | 24 | -0.33 | 1.69 |
| THC Placebo Arm | 24 | -0.17 | 1.13 |
| AMP Arm | 24 | 1.92 | 4.03 |
| ALC Arm | 24 | -1.29 | 1.88 |
| THC Arm | 24 | -0.67 | 2.37 |
| AMP Placebo Arm | 24 | 0.33 | 1.24 |
| ALC Placebo Arm | 24 | -1.08 | 3.01 |
| THC Placebo Arm | 24 | -0.17 | 0.82 |
| AMP Arm | 24 | 0.46 | 1.91 |
| ALC Arm | 24 | 0.54 | 1.02 |
| THC Arm | 24 | 0.54 | 1.82 |
| AMP Placebo Arm | 24 | 0.04 | 1.04 |
| ALC Placebo Arm | 24 | -0.04 | 0.81 |
| THC Placebo Arm | 24 | 0.04 | 0.95 |
| AMP Arm | 24 | 1.13 | 2.15 |
| ALC Arm | 24 | -1.5 | 1.47 |
| THC Arm | 24 | -1.29 | 1.78 |
| AMP Placebo Arm | 24 | -0.33 | 1.13 |
| ALC Placebo Arm | 24 | -0.38 | 1.41 |
| THC Placebo Arm | 24 | -0.29 | 1.20 |
| AMP Arm | 24 | -0.46 | 1.93 |
| ALC Arm | 24 | 3.63 | 3.01 |
| THC Arm | 24 | 2.13 | 3.43 |
| AMP Placebo Arm | 24 | 0.21 | 2.50 |
| ALC Placebo Arm | 24 | 0.71 | 2.73 |
| THC Placebo Arm | 24 | 0.42 | 1.59 |
| AMP Arm | 24 | 1.21 | 1.59 |
| ALC Arm | 24 | 0.08 | 1.02 |
| THC Arm | 24 | 0.71 | 1.94 |
| AMP Placebo Arm | 24 | 0.13 | 0.68 |
| ALC Placebo Arm | 24 | -0.13 | 0.74 |
| THC Placebo Arm | 24 | -0.08 | 0.28 |
Specific drug effects will be measured using the Addiction Research Center Inventory (Martin et al. 1971). The ARCI measures effects specific to drug classes, including the effects of AMP-like drugs (A scale, 0 to 11), morphine and benzedrine like drugs (MBG scale, 0 to 14), lysergic acid-like drugs (LSD scale, 0 to 14), benzedrine-like drugs (BG scale, 0 to 13), pentobarbital-chlorpromazine and ALC-like drugs (PCAG scale, 0 to 15), and cannabis-like drugs (M scale, 0 to 12). We used this questionnaire as a manipulation check to ensure that the drugs produced their typical drug-specific effects in this study. For example, zero value of A sacle would be minimum report of amphetamine-like drug effects, and 11 would be maximum report of amphetamine-like effects.The change in ARCI was assessed by the difference in measurements between baseline and 210 minutes after drink administration. Baseline was measure 15 minutes prior to capsule administration.
Population: Participants who completed all sessions
| Group | N | Value | Spread / interval |
|---|---|---|---|
| AMP Arm | 24 | 1.0 | 1.93 |
| ALC Arm | 24 | -0.71 | 1.20 |
| THC Arm | 24 | -0.46 | 1.06 |
| AMP Placebo Arm | 24 | -0.17 | 0.82 |
| ALC Placebo Arm | 24 | -0.54 | 1.50 |
| THC Placebo Arm | 24 | 0.08 | 1.21 |
| AMP Arm | 24 | 1.38 | 3.31 |
| ALC Arm | 24 | -1.17 | 2.08 |
| THC Arm | 24 | -0.88 | 1.92 |
| AMP Placebo Arm | 24 | 0.13 | 1.15 |
| ALC Placebo Arm | 24 | -0.79 | 2.95 |
| THC Placebo Arm | 24 | 0.04 | 0.86 |
| AMP Arm | 24 | 0.63 | 1.79 |
| ALC Arm | 24 | 0.33 | 0.92 |
| THC Arm | 24 | 0.54 | 1.22 |
| AMP Placebo Arm | 24 | 0.25 | 0.90 |
| ALC Placebo Arm | 24 | 1.67 | 0.87 |
| THC Placebo Arm | 24 | 0.04 | 1.04 |
| AMP Arm | 24 | 0.83 | 1.61 |
| ALC Arm | 24 | -1.25 | 1.39 |
| THC Arm | 24 | -0.83 | 1.40 |
| AMP Placebo Arm | 24 | -0.17 | 0.82 |
| ALC Placebo Arm | 24 | -0.38 | 1.06 |
| THC Placebo Arm | 24 | -0.13 | 1.48 |
| AMP Arm | 24 | -0.29 | 2.10 |
| ALC Arm | 24 | 3.17 | 3.17 |
| THC Arm | 24 | 1.04 | 1.76 |
| AMP Placebo Arm | 24 | -0.29 | 1.43 |
| ALC Placebo Arm | 24 | 0.21 | 2.55 |
| THC Placebo Arm | 24 | 0.13 | 1.68 |
| AMP Arm | 24 | 0.96 | 1.97 |
| ALC Arm | 24 | 0.08 | 0.97 |
| THC Arm | 24 | 0.21 | 0.72 |
| AMP Placebo Arm | 24 | 0 | 0.42 |
| ALC Placebo Arm | 24 | -0.17 | 0.70 |
| THC Placebo Arm | 24 | -0.08 | 0.28 |
| Milestone | Healthy Adult Volunteers |
|---|---|
| STARTED | 28 |
| COMPLETED | 24 |
| NOT COMPLETED | 4 |
| Event | System | Groups: affected / at risk |
|---|---|---|
| vomiting from alcohol dose | Gastrointestinal disorders | Healthy Adult Volunteers: 1 / 28 |
Time frame: Measured 15 minutes prior to capsule administration and 150 minutes after drink administration.
Drug effects will be measured using the Drug Effects Questionnaire (Fischman \& Foltin, 1991). The DEQ included 5 subscales; feeling, liking, and disliking the drug effect, feeling high, and wanting more of the drug. Each subscale ranged from 1(Not at all) to 100(Very much). The change in DFQ was assessed by the difference in measurements between baseline and 150 minutes after drink administration. Baseline was measure 15 minutes prior to capsule administration.
Time frame: Measured 15 minutes prior to capsule administration and 180 minutes after drink administration.
Drug effects will be measured using the Drug Effects Questionnaire (Fischman \& Foltin, 1991). The DEQ included 5 subscales; feeling, liking, and disliking the drug effect, feeling high, and wanting more of the drug. Each subscale ranged from 1(Not at all) to 100(Very much). The change in DFQ was assessed by the difference in measurements between baseline and 180 minutes after drink administration. Baseline was measure 15 minutes prior to capsule administration.
Time frame: Measured 15 minutes prior to capsule administration and 210 minutes after drink administration.
Drug effects will be measured using the Drug Effects Questionnaire (Fischman \& Foltin, 1991). The DEQ included 5 subscales; feeling, liking, and disliking the drug effect, feeling high, and wanting more of the drug. Each subscale ranged from 1(Not at all) to 100(Very much). The change in DFQ was assessed by the difference in measurements between baseline and 210 minutes after drink administration. Baseline was measure 15 minutes prior to capsule administration.
Time frame: Measured 15 minutes prior to capsule administration and 30 minutes after capsule administration and before drink administration
Specific drug effects will be measured using the Addiction Research Center Inventory (Martin et al. 1971). The ARCI measures effects specific to drug classes, including the effects of AMP-like drugs (A scale, 0 to 11), morphine and benzedrine like drugs (MBG scale, 0 to 14), lysergic acid-like drugs (LSD scale, 0 to 14), benzedrine-like drugs (BG scale, 0 to 13), pentobarbital-chlorpromazine and ALC-like drugs (PCAG scale, 0 to 15), and cannabis-like drugs (M scale, 0 to 12). We used this questionnaire as a manipulation check to ensure that the drugs produced their typical drug-specific effects in this study. For example, zero value of A sacle would be minimum report of amphetamine-like drug effects, and 11 would be maximum report of amphetamine-like effects. The change in ARCI was assessed by the difference in measurements between baseline and 30 minutes after capsule administration and before drink administration. Baseline was measure 15 minutes prior to capsule administration.
Time frame: Measured 15 minutes prior to capsule administration and 30 minutes after drink administration
Specific drug effects will be measured using the Addiction Research Center Inventory (Martin et al. 1971). The ARCI measures effects specific to drug classes, including the effects of AMP-like drugs (A scale, 0 to 11), morphine and benzedrine like drugs (MBG scale, 0 to 14), lysergic acid-like drugs (LSD scale, 0 to 14), benzedrine-like drugs (BG scale, 0 to 13), pentobarbital-chlorpromazine and ALC-like drugs (PCAG scale, 0 to 15), and cannabis-like drugs (M scale, 0 to 12). We used this questionnaire as a manipulation check to ensure that the drugs produced their typical drug-specific effects in this study. For example, zero value of A sacle would be minimum report of amphetamine-like drug effects, and 11 would be maximum report of amphetamine-like effects. The change in ARCI was assessed by the difference in measurements between baseline and 30 minutes after drink administration. Baseline was measure 15 minutes prior to capsule administration.
Time frame: Measured 15 minutes prior to capsule administration and 90 minutes after drink administration
Specific drug effects will be measured using the Addiction Research Center Inventory (Martin et al. 1971). The ARCI measures effects specific to drug classes, including the effects of AMP-like drugs (A scale, 0 to 11), morphine and benzedrine like drugs (MBG scale, 0 to 14), lysergic acid-like drugs (LSD scale, 0 to 14), benzedrine-like drugs (BG scale, 0 to 13), pentobarbital-chlorpromazine and ALC-like drugs (PCAG scale, 0 to 15), and cannabis-like drugs (M scale, 0 to 12). We used this questionnaire as a manipulation check to ensure that the drugs produced their typical drug-specific effects in this study. For example, zero value of A sacle would be minimum report of amphetamine-like drug effects, and 11 would be maximum report of amphetamine-like effects. The change in ARCI was assessed by the difference in measurements between baseline and 90 minutes after drink administration. Baseline was measure 15 minutes prior to capsule administration.
Time frame: Measured 15 minutes prior to capsule administration and 120 minutes after drink administration
Specific drug effects will be measured using the Addiction Research Center Inventory (Martin et al. 1971). The ARCI measures effects specific to drug classes, including the effects of AMP-like drugs (A scale, 0 to 11), morphine and benzedrine like drugs (MBG scale, 0 to 14), lysergic acid-like drugs (LSD scale, 0 to 14), benzedrine-like drugs (BG scale, 0 to 13), pentobarbital-chlorpromazine and ALC-like drugs (PCAG scale, 0 to 15), and cannabis-like drugs (M scale, 0 to 12). We used this questionnaire as a manipulation check to ensure that the drugs produced their typical drug-specific effects in this study. For example, zero value of A sacle would be minimum report of amphetamine-like drug effects, and 11 would be maximum report of amphetamine-like effects.The change in ARCI was assessed by the difference in measurements between baseline and 120 minutes after drink administration. Baseline was measure 15 minutes prior to capsule administration.
Time frame: Measured 15 minutes prior to capsule administration and 150 minutes after drink administration
Specific drug effects will be measured using the Addiction Research Center Inventory (Martin et al. 1971). The ARCI measures effects specific to drug classes, including the effects of AMP-like drugs (A scale, 0 to 11), morphine and benzedrine like drugs (MBG scale, 0 to 14), lysergic acid-like drugs (LSD scale, 0 to 14), benzedrine-like drugs (BG scale, 0 to 13), pentobarbital-chlorpromazine and ALC-like drugs (PCAG scale, 0 to 15), and cannabis-like drugs (M scale, 0 to 12). We used this questionnaire as a manipulation check to ensure that the drugs produced their typical drug-specific effects in this study. For example, zero value of A sacle would be minimum report of amphetamine-like drug effects, and 11 would be maximum report of amphetamine-like effects.The change in ARCI was assessed by the difference in measurements between baseline and 150 minutes after drink administration. Baseline was measure 15 minutes prior to capsule administration.
Time frame: Measured 15 minutes prior to capsule administration and 180 minutes after drink administration
Specific drug effects will be measured using the Addiction Research Center Inventory (Martin et al. 1971). The ARCI measures effects specific to drug classes, including the effects of AMP-like drugs (A scale, 0 to 11), morphine and benzedrine like drugs (MBG scale, 0 to 14), lysergic acid-like drugs (LSD scale, 0 to 14), benzedrine-like drugs (BG scale, 0 to 13), pentobarbital-chlorpromazine and ALC-like drugs (PCAG scale, 0 to 15), and cannabis-like drugs (M scale, 0 to 12). We used this questionnaire as a manipulation check to ensure that the drugs produced their typical drug-specific effects in this study. For example, zero value of A sacle would be minimum report of amphetamine-like drug effects, and 11 would be maximum report of amphetamine-like effects.The change in ARCI was assessed by the difference in measurements between baseline and 180 minutes after drink administration. Baseline was measure 15 minutes prior to capsule administration.
Time frame: Measured 15 minutes prior to capsule administration and 210 minutes after drink administration
Specific drug effects will be measured using the Addiction Research Center Inventory (Martin et al. 1971). The ARCI measures effects specific to drug classes, including the effects of AMP-like drugs (A scale, 0 to 11), morphine and benzedrine like drugs (MBG scale, 0 to 14), lysergic acid-like drugs (LSD scale, 0 to 14), benzedrine-like drugs (BG scale, 0 to 13), pentobarbital-chlorpromazine and ALC-like drugs (PCAG scale, 0 to 15), and cannabis-like drugs (M scale, 0 to 12). We used this questionnaire as a manipulation check to ensure that the drugs produced their typical drug-specific effects in this study. For example, zero value of A sacle would be minimum report of amphetamine-like drug effects, and 11 would be maximum report of amphetamine-like effects.The change in ARCI was assessed by the difference in measurements between baseline and 210 minutes after drink administration. Baseline was measure 15 minutes prior to capsule administration.